Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414691 | 0.88 | PTGDR2 (0.54) | PTGDR2PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3417167 | 0.86 | PTGDR2 (0.53) | PTGDR2KITALOX15HTT | |
| SCHEMBL3416767 | 0.84 | PTGDR2 (0.50) | PTGDR2GRM5ALOX15HTT | |
| SCHEMBL3410196 | 0.82 | PTGDR2 (0.45) | PTGDR2GRM5KIT | |
| SCHEMBL4319434 | 0.80 | KDM4E (0.48) | — | |
| SCHEMBL4314110 | 0.80 | PTGDR2 (0.46) | PTGDR2KITALOX15HTT | |
| SCHEMBL3411080 | 0.80 | PTGDR2 (0.46) | PTGDR2PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL1015940 | 0.80 | XDH (0.51) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL4319840 | 0.79 | MEN1 (0.52) | — | |
| SCHEMBL3415259 | 0.79 | KIT (0.52) | PTGDR2GRM5KITALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010124047-A1 | BISARYL ALKYNYLAMIDES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124047-A1 | BISARYL ALKYNYLAMIDES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009143404-A1 | PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION | WYETH (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | PTGDR2 500/4885PDE4D 1044/4885PDE4B 919/4885 |
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | GRM5, GRM1, GRM2 | PTGDR2 554/4885PDE4D 1192/4885PDE4B 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.